The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Open accessAbstract
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy and chemotherapy. Finally, the major unanswered questions on the drug are outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaupel, P. W., Schlenger, K., Knoop, C., & Höckel, M. (1991) · PubMed · Cited by 952
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, G. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90002-8 · Cited by 798
Bioactivation as a Model for Drug Design Bioreductive Alkylation
Moore, H. W. (1977) · Science · doi:10.1126/science.877572 · Cited by 430
Definitive evidence for hypoxic cells influencing cure in cancer therapy.
Bush, R. S., Jenkin, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H. A., Dembo, A. J., & Pringle, J. F. (1978) · PubMed Central · Cited by 416
Tumor hypoxia: its impact on cancer therapy
Moulder, J. E., & Rockwell, S. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00055376 · Cited by 414
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Self-citationOxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements.
Höckel, M., Schlenger, K., Knoop, C., & Vaupel, P. W. (1991) · PubMed · Cited by 350
Cornforth, M. N., & Bedford, J. S. (1987) · Radiation Research · doi:10.2307/3576926 · Cited by 332
RADIOTHERAPY AND HYPERBARIC OXYGEN IN HEAD AND NECK CANCER
Henk, J. M., & Smith, C. W. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90117-9 · Cited by 320
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Sartorelli, A. C. (1988) · PubMed · Cited by 278
Overgaard, J., Sand Hansen, H., Jøsrgensen, K., & Hjelm Hansen, M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90058-1 · Cited by 239
Potential bioreductive alkylating agents. 1. Benzoquinone derivatives
Lin, A. J., Cosby, L. A., Shansky, C. W., & Sartorelli, A. C. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00282a011 · Cited by 198
Brown, J. M., & Lemmon, M. J. (1990) · PubMed · Cited by 181
Self-citationLaderoute, K., Wardman, P., & Rauth, A. M. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90010-x · Cited by 158
Intracapillary oxyhemoglobin saturation of malignant tumors in humans
Mueller‐Klieser, W., Vaupel, P. W., Manz, R., & Schmidseder, R. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90036-5 · Cited by 130
Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.
Baker, M., Zeman, E. M., Hirst, V. K., & Brown, J. M. (1988) · PubMed · Cited by 121
Self-citationPrise, K. M., Davies, S., & Michael, B. D. (1987) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008714552481 · Cited by 115
Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions
Tannock, I. F., & Guttman, P. (1981) · British Journal of Cancer · doi:10.1038/bjc.1981.37 · Cited by 114
Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs
Voorhees, W. D., & Babbs, C. F. (1982) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(82)90252-8 · Cited by 109
Hypoxic fractions of human tumors xenografted into mice: A review
Rockwell, S., & Moulder, J. E. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90154-c · Cited by 109
RSU 1069, a nitroimidazole containing an aziridine group
Stratford, I. J., O’Neill, P., SHELDON, P. W., Silver, A. R., Walling, J. M., & ADAMS, G. E. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90566-6 · Cited by 103
Modification of chemotherapy by nitroimidazoles
Siemann, D. W. (1984) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(84)90508-x · Cited by 102
Wang, J., Biedermann, K. A., & Brown, J. M. (1992) · PubMed · Cited by 98
Self-citationEnhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
Zeman, E. M., Hirst, V. K., Lemmon, M. J., & Brown, J. M. (1988) · Radiotherapy and Oncology · doi:10.1016/0167-8140(88)90263-0 · Cited by 94
Self-citationTaylor, Y. C., & Rauth, A. M. (1978) · PubMed · Cited by 92
Therapeutic Advantage of Hypoxic Cells in Tumors: A Theoretical Study
Brown, J. M., & Koong, A. C. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.3.178 · Cited by 91
Self-citationKoch, C. J. (1984) · Radiation Research · doi:10.2307/3576294 · Cited by 89
Hypoxic cells as specific drug targets for chemotherapy.
Ka, K. (1987) · PubMed · Cited by 88
Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation
Brown, J. M., & Lemmon, M. J. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90057-b · Cited by 85
Self-citationWalton, M. I., Wolf, C. R., & Workman, P. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90007-6 · Cited by 79
The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
Stratford, I. J., & Stephens, M. A. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90898-5 · Cited by 79
Potential Bioreductive Alkylating Agents
Ai, L., Cosby, L. A., & Sartorelli, A. C. (1976) · ACS symposium series · doi:10.1021/bk-1976-0030.ch004 · Cited by 78
Hypoxia-mediated druGS FOR RADIATION AND CHEMOTHERAPY
ADAMS, G. E. (1981) · Cancer · Cited by 77
Enzymology of the reductive bioactivation of SR 4233
Walton, M. I., & Workman, P. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90119-6 · Cited by 69
Breakage of Human Interphase Chromosomes by Alpha Particles and X-rays
Bedford, J. S., & GOODHEAD, D. T. (1989) · International Journal of Radiation Biology · doi:10.1080/09553008914550261 · Cited by 68
Fracasso, P. M., & Sartorelli, A. C. (1986) · PubMed · Cited by 60
Rockwell, S., Kennedy, K. A., & Sartorelli, A. C. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90728-3 · Cited by 59
Rs, M., & Rauth, A. M. (1986) · PubMed · Cited by 56
Pre- and post-irradiation adiosensitization by SR 4233
Zeman, E. M., & Brown, J. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90897-3 · Cited by 48
Self-citationSun, J. R., & Brown, J. M. (1989) · PubMed · Cited by 44
Self-citationADAMS, G. E., Stratford, I. J., Edwards, H. S., Bremner, J. C. M., & Cole, S. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90510-o · Cited by 42
Enhancement of Alkylating Agent Activity by SR-4233 in the FSaIIC Muraine Fibrosarcoma
Holden, S. A., Teicher, B. A., Ara, G., Herman, T., & Coleman, C. N. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.3.187 · Cited by 42
Tannock, I. F. (1980) · British Journal of Cancer · doi:10.1038/bjc.1980.334 · Cited by 35
Costa, A. K., Baker, M. A., Brown, J. M., & Trudell, J. R. (1989) · PubMed · Cited by 34
Self-citation
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
Tang, Z., Liu, Y., He, M., & Bu, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201805664 · Cited by 1,951
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Metadata
- Authors
- Brown, J.
- Venue
- British Journal of Cancer
- Published
- 1993-06
- Volume
- 67
- Issue
- 6
- Pages
- 1163-1170
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2145953677
- Cited by
- 366
- References
- 44
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.